Concurrent KIAA1549-BRAF fusion and chromosome 1p deletion with or without concomitant chromosome 19q loss are recurrent molecular alterations in the diffuse leptomeningeal glioneuronal tumor (DLGNT) [6, 7, 10] , in which widespread leptomeningeal dissemination is a diagnostic feature [1, 6, 10] . We have reviewed five spinal cord tumors ( Table 1 ) that show the morphologic and molecular genetic characteristics of DLGNT, but in which radiographically apparent leptomeningeal dissemination was not identified at presentation. At the initial review, we sought to understand the relationship between these tumors and DLGNT by undertaking immunohistochemical analyses with a panel of neural markers: GFAP, OLIG2, and synaptophysin, and with antibodies to the BRAF V600E, histone H3.1/H3.3 K27 M, and IDH1 R132H mutant proteins. Duplication of chromosome 7q34 (a surrogate marker for the presence of KIAA1549-BRAF fusion) and deletion of chromosome cord tumors in our series contained many oligodendrocyte-like cells (OLCs), which either infiltrated spinal cord parenchyma or grew in small nests (Table 1; Fig. 2 ). By immunohistochemistry, they expressed OLIG2 and synaptophysin, but not GFAP. All contained rare neuropil-like islands, which were often surrounded by tumor cells with neurocytic differentiation and had a rosette-like configuration, a feature distinct from the conventional low-grade ganglion cell tumors. The rosetted neuropil islands were much larger than similar structures in the rosette-forming glioneuronal tumor. Glial foci resembling pilocytic astrocytoma (PA) were also evident. Mitotic counts (<1/10 hpfs) and Ki-67 immunolabeling (<5%) were low, in line with our experience of DLGNTs. While leptomeningeal spread was not found radiographically, microscopic leptomeningeal involvement was identified at the site of biopsy in four cases.
Chromosome 7q34 duplication, a surrogate marker for the presence of KIAA1549-BRAF fusions, was identified in all five cases by iFISH ( Table 2 ). The presence of fusion transcripts was further confirmed in four cases tested by RT-PCR. In two cases, exon 15 of KIAA1549 was fused to exon 9 of BRAF (15-9), which is also commonly seen in extra-cerebellar midline PAs [2] . The 15-11 fusion seen in case #3 is occasionally found in supratentorial PAs [5] . Both 15-9 and 15-11 fusions have been detected in DLGNTs at our institution. The 13-11 fusion in case #4 occurs rarely in PAs [11] . Chromosome 1p loss was present in all five cases. Chromosome 19q loss was not identified in the four cases tested. Immunostains for BRAF V600E, histone H3 K27M, and IDH1 R132H mutant proteins were negative in tumors with sufficient tissue for testing.
The spinal tumors in our series share the patient demographics, radiologic characteristics, morphologic features, and genetic alterations of DLGNTs, but lack overt leptomeningeal dissemination at presentation and during followup. When a parenchymal mass is present in a DLGNT, it is often in the spinal cord. Our findings suggest that a lowgrade glioneuronal tumor with the same features can also present as a solitary spinal cord mass. Since DLGNTs demonstrate slow, but nonetheless relentless and debilitating clinical progression [1, 4, 6, 8] , it would be prudent to follow such intramedullary tumors closely to understand their long-term clinical outcome. However, our findings suggest that DLGNTs form a spectrum with tumors that have no 
obvious leptomeningeal dissemination at presentation, which has implications for the DLGNT's provisional status in the latest WHO classification.
